Sumitomo Pharma America reports early Phase 1/2 data for SMP-3124LP CHK1 inhibitor at ASCO 2026

  • Sumitomo Pharma America presented first clinical data at ASCO 2026 from a first-in-human Phase 1/2 trial of SMP-3124LP in advanced solid tumors.
  • Early results showed the investigational CHK1 inhibitor was generally well tolerated, with side effects described as manageable in heavily pretreated patients.
  • The study also showed early signs of anti-tumor activity, supporting further development of the liposomal delivery approach intended to improve the benefit-risk profile.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sumitomo Pharma Co. Ltd. published the original content used to generate this news brief on June 02, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.